Listing of Additional Shares. The Company shall have submitted a Listing of Additional Shares Notification with the Nasdaq covering all of the Shares.
Appears in 8 contracts
Sources: Common Stock Purchase Agreement (Exicure, Inc.), Common Stock Purchase Agreement (Exicure, Inc.), Common Stock Purchase Agreement (Exicure, Inc.)
Listing of Additional Shares. The Company shall have submitted a Listing of Additional Shares Notification with the Nasdaq covering all of the SharesSecurities.
Appears in 4 contracts
Sources: Securities Purchase Agreement (Taysha Gene Therapies, Inc.), Securities Purchase Agreement (Landos Biopharma, Inc.), Securities Purchase Agreement (PLx Pharma Inc.)
Listing of Additional Shares. The Company shall have submitted a Listing of Additional Shares Notification with the Nasdaq covering all of the Shares and the Warrant Shares.
Appears in 2 contracts
Sources: Securities Purchase Agreement (Kura Oncology, Inc.), Securities Purchase Agreement (Tempest Therapeutics, Inc.)
Listing of Additional Shares. The Company shall have submitted a Listing of Additional Shares Notification with the Nasdaq covering all of the Sharesshares exercisable upon conversion of the 2019 Warrants.
Appears in 2 contracts
Sources: Securities Issuance Agreement (Ziopharm Oncology Inc), Securities Issuance Agreement (Ziopharm Oncology Inc)
Listing of Additional Shares. The Company shall have submitted a Listing of Additional Shares Notification with the Nasdaq covering all of the SharesShares (subject to the Exchange Cap).
Appears in 1 contract